Page 56 - journal-8-23-Full

Òˆˆ «“√ “√°“√·æ∑¬ ¬·º√ “√ · °“√≈– ∑¬åå∑“߇≈◊Õ° ªï∑’Ë ¯©∫—∫∑’Ë Ú-Û æƒ…¿“§¡-∏—𫓧¡ ÚııÛ
°“√ ∑ å π‰∑¬
∑“
«“√ “√°“√·æ∑¬å·ºπ‰∑¬·≈–°“√·æ∑¬
√ “√°“√ ∑¬å·ºπ‰∑¬·≈–°“√ ∑¬å∑“å·ºπ‰∑¬·≈–°“√·æ∑¬å∑“߇≈◊Õ°
°“√‡μ√’¬¡‡ªìπ “√ª√–°Õ∫‡™‘ß´âÕπ√–À«à“ß “√ °—¥ ¡ÿπ‰æ√ ‚¥¬¡’§à“ IC μË”∑’Ë ÿ¥∑’Ë Ûˆ.¯ ¡§°./¡≈. √Õß≈ß¡“§◊Õ MO-
50
·≈– polyvinylpyrrolidone 40000 (PVP complex) à«π 1, TT1, Nn-E1, Ab-E2, Ab-E1, PG-E1, Ab-E3, PG-Ec,
“√ °—¥ AG ≈–≈“¬„π Ò% DMSO ‚¥¬· ¥ß¥—ßμ“√“ß∑’Ë Ú Ab-E5, Nn-E4, Nn-Ec, TTW, Nn-E2, GP-E, PG-E2, MO-
Ù. °“√∑¥ Õ∫ƒ∑∏‘Ϭ—∫¬—Èß°“√∑”ß“π¢Õ߇Õπ‰´¡å pan- 2 ·≈– AG-SFE “√∑’ˉ¡à “¡“√∂À“§à“¡’ Ú ™π‘¥ ‰¥â·°à Ab-

creatic lipase ¢Õß “√ °—¥μ—«Õ¬à“ß E4 æ∫«à“¡’ƒ∑∏‘Ϭ—∫¬—Èß pancreatic lipase ‰¥âμË”¡“°μâÕß„™â
‡μ√’¬¡ “√ °—¥ ¡ÿπ‰æ√∑’˧«“¡‡¢â¡¢âπμà“ß Ê ®“°π—Èπ “√„𧫓¡‡¢â¡¢âπ Ÿß¡“°°«à“ Ú, ¡§°./¡≈. à«π “√ °—¥
ªî‡ªμ “√ °—¥¡“ Úı ‰¡‚§√≈‘μ√ ·≈â«‡μ‘¡ buffer (Tris-HCl, AG ´÷Ëß¡’ª√‘¡“≥‰¡à‡æ’¬ßæÕ„π°“√‡μ√’¬¡„𧫓¡‡¢â¡¢âπ∑’Ë Ÿß¢÷Èπ

NaCl, CaCl ) ∑’Ë¡’§à“ pH 8.0 ·≈â«®÷ß„ à‡Õπ‰´¡å pancreatic ·μஓ°¢âÕ¡Ÿ≈∑’Ë¡’ “¡“√∂ª√–¡“≥§à“ IC «à“Õ¬Ÿà√–À«à“ß Ò-
2 50
lipase ≈߉ª Úı ‰¡‚§√≈‘μ√ ·≈–¢—ÈπμÕπ ÿ¥∑⓬®÷ß‡μ‘¡ 4- Ú ¡§°./¡≈.

methylumbelliferyl oleate (4-MU oleate) ´÷Ë߇ªìπ substrate
≈߉ª Ò ‰¡‚§√≈‘μ√ ®“°π—Èπ𔉪∫ࡉ«â∑’Ë Úı˚´ ª√–¡“≥ Û
π“∑’ ·≈â«®÷ß𔉪«—¥§à“°“√∑”ß“π¢Õ߇Õπ‰´¡å pancreatic li- μ“√“ß∑’Ë Û ƒ∑∏‘Ï¢Õß “√ °—¥ ¡ÿπ‰æ√μàÕ°“√¬—∫¬—Èß°“√∑”ß“π¢Õß
‡Õπ‰´¡å pancreatic lipase
pase ‚¥¬«‘∏’ fluorometrically ∑’Ë excitation Ûˆ π“‚π‡¡μ√
·≈– emission ıÛı π“‚π‡¡μ√ ´÷Ëß„π°“√∑¥≈Õßπ’È®–„™â ƒ∑∏‘Ϭ—∫¬—È߇Õπ‰´¡å

orlistat ‡ªìπ positive control ≈”¥—∫∑’Ë “√ °—¥ pancreatic lipase
{IC (¡§°./¡≈.)}
ı. °“√«—¥°“√∑”ß“π¢Õ߇Õπ‰´¡å HMG-CoA reduc- 50
tase Ò Nn-E3 Ûˆ.¯
Ú MO-1 ı¯.Û
°“√∑”ß“π¢Õ߇Õπ‰´¡å HMG-CoA reductase «—¥‚¥¬
Û TT1 ÒÚÛ.Ò
„™â HMG-CoA reductase assay kit. HMG-CoA „™â‡ªìπ
Ù Nn-E1 ÒÛÒ.
“√μ—Èßμâπ à«π°“√≈¥≈ߢÕß NADPH ª√–‡¡‘π‚¥¬«—¥°“√
ı Ab-E2 ÒÛ¯.Ù
¥Ÿ¥°≈◊π· ß∑’˧«“¡¬“«§≈◊Ëπ ÛÙ π¡. ·≈–Õÿ≥À¿Ÿ¡‘ Û˜˚´ ˆ Ab-E1 ÒıÙ.Û
‚¥¬«—¥‡ªìπ kinetic ‚¥¬°“√∑¥≈Õßπ’È„™â¬“ pravastatin ‡ªìπ ˜ AG Ò-Ú*
¯ PG-E1 Ú¯.Ò
positive control
˘ Ab-E3 ÚÛÒ.Û
º≈°“√∑¥≈Õß Ò PG-Ec ÚÙÒ.˘
ÒÒ Ab-E5 ÛıÒ.Ò
®“°°“√∑¥ Õ∫ƒ∑∏‘Ϭ—∫¬—Èß°“√∑”ß“π¢Õ߇Õπ‰´¡å pan- ÒÚ Nn-E4 Û¯.ˆ
creatic lipase „πÀ≈Õ¥∑¥≈Õß (in vitro enzymatic as- ÒÛ Nn-Ec Û˘¯.Û
say) ¢Õß “√ °—¥ ¡ÿπ‰æ√®”π«π Ú ™π‘¥ “√ °—¥ ‚¥¬„™â ÒÙ TTW ÙÙ.Ú
Òı Nn-E2 ıÒÒ.Ú
§«“¡‡¢â¡¢âπ∑’Ëμà“ß Ê °—π ·≈â«π”§à“‡©≈’ˬ∑’ˉ¥â®“°°“√∑”´È” Û
Òˆ GP-E ˆÒ¯.
§√—Èß „π·μà≈–§«“¡‡¢â¡¢âπ¡“§”π«π§à“ IC ®“° dose-re-
50
Ò˜ PG-E2 ¯˜.¯
sponse curve ¢Õß “√ °—¥·μà≈–™π‘¥‚¥¬„™â Prism program
Ò¯ MO-2 ¯ÙÛ.˜
·≈–„™â orlistat ‡ªìπ positive control ‚¥¬„™â 4-MU oleate Ò˘ AG-SFE ÒÚ˘.
‡ªìπ substrate ·≈–º≈∑’ˉ¥â®“°ªØ‘°‘√‘¬“ §◊Õ 4-methylum- Ú Ab-E4 > Ú,.

belliferone ∑’˪≈¥ª≈àÕ¬ÕÕ°¡“‚¥¬°“√«—¥‡ªìπª√‘¡“≥ §à“ À¡“¬‡Àμÿ Ò. * ‡ªìπ§à“ IC 50 ‚¥¬ª√–¡“≥ ‡π◊ËÕß®“° “√¡’ª√‘¡“≥‰¡à‡æ’¬ßæÕ
®÷߉¡à “¡“√∂‡æ‘Ë¡§«“¡‡¢â¡¢âπ‰¥âÕ’°
fluorescence
Ú. º≈°“√∑¥≈Õß· ¥ß‡ªìπ§à“‡©≈’ˬ (Mean ± SEM) ®“° Û °“√
∑¥ Õ∫‚¥¬·μà≈–§√—Èß∑”´È” Û §√—Èß
º≈°“√∑¥≈Õß · ¥ß„πμ“√“ß∑’Ë Û æ∫«à“ Nn-E3 “¡“√∂
Û. “√ °—¥ AG ≈–≈“¬„π DMSO “√ °—¥Õ◊ËπÊ ≈–≈“¬„ππÈ”
¬—∫¬—Èß°“√∑”ß“π¢Õ߇Õπ‰´¡å pancreatic lipase ‰¥â¥’∑’Ë ÿ¥ Ù. Positive control §◊Õ .Úı mM Orlistat